Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What's your explanation why there was no reverse split for the past 3 years? I started imagining this stock somehow will not need to do one "forever", but have no reason to justify that hope either. What exactly is the tipping point which will make the company do a reverse split?
I will say frankly at this point that the main reason I am not bailing the stock is that I can't digest the loss. But seeing the price be lifted from 0.4 to 4.0 on an RS and then dilute back down to 0.4 would simply be too much of a torment. They simply must back up an RS with some proper news so that it can find new reason to hold that level.
A million shares traded and it went down 20+ cents.
Why isn't Chris Recknor on the cc? I don't like that. They are communicating once in a blue moon and someone we think to be important part of the team is missing; why not be present even if only for a few words on what to look for going forward.
Logically it may mean the call will lack much scientific/research substance.
Questions in my head:
What can management possibly be doing behind the scenes?
What is the best possible news that we can practically expect next?
What is the worst possible?
Is the management still working for making LL a success, or are they in the process of winding down having given up? Do they still believe in LL as a ground-breaking molecule or that they can break through all the obstacles to getting approval? What is their goal and path?
The complete silence is not boosting morale. I feel like the captaincy of the ship has lost direction, like they have nothing material to speak about or hope about and hence are silent. Say something!
What still requires explanation is why the price went from .30 to .80 and staying there in spite of 10-k, management shuffling and everything else that people think is bad? Price goes up because people bought in or shorts sold out, and that happens when they think the reward outweighs the risk of being invested. If the new President was catalyst, then the lack of good news is not causing a serious sell off, which means for now that the market (of post 30 cent investors) is not agreeing with the shorts on this board.
Its a good run but longs have to be alert for a rug-pull. I don't think it matters for most of us already in here; but a new batch of "investors" get sucked in at the higher prices and will likely stay as bag-holders unless the company pulls out real results.
Of course it is possible that something material is happening behind the scenes but that would be "secret" to buyers, right? So as of now, the run is happening on anticipation and expectation, as before. Except the management is creating a solid impression and projecting confidence and discipline; and those who went out likely think it is the right time and price to get back in.
but why is 700 not working as well as 350 on NASH? Any explanation?
what does that have to do with her post?
Possible the board member objected to the current decisions being made for the sake of survival and was voted out; and he quit. The PR today looks more like pragmatism than an honest reflection of the events of the past and people who were involved. Pestell's name is of more value now than Nader's for the company; in fact Nader can be framed usefully as the antagonist who brought disrepute to the company and as the only cause for all its problems. Now the company can burn him as needed to cleanse its own reputation, "as part of our comprehensive efforts to restore credibility with the medical and scientific communities."
Actually, stepping back a bit, even if such acrimony is unfair to Nader and the past sequence of events/decisions, what's happening now may be in the best interests of shareholders. Its the world of business and we are playing according to the tunes of the Powers that be.
Company is publicly turning on Nader, that’s for sure. Seems weak but may be best way forward. If they cozy up to Pestell, perhaps he will wait for $3 to exercise the warrants, perhaps some tacit agreement of that sort.
Anyone recall what Nader accused Pestell of doing, that company now regrets?
I heard that VERU cc from link that was posted here yesterday. The CEO says they are checking their endpoints for 60 days instead of the usual 28. After 28, their placebo had 35% mortality which he said was the same as the Lancelet study for Tocilizumab. And he argued mortality is expected to increase for 60 days. Main point is that the "FDA agreed" to no additional data needed for efficacy etc. I don't see how given the way he said things they are not going to get the EUA. Can see it in the market reaction today as well.
Of course, we still have a chance to prove Leronlimab's worth in the Brazil trials. I thought that will be significant for us, just to prove the drug's efficacy in a certain condition that is more generally applicable than just for covid. But the trials are still suspended a month after DSMC approved the restart and Cytodyn said to have asked for ANVISA's permission. It is quite possible, given the financial situation and the waning of the pandemic, that the company is shifting to the other indications.
They got this in the bag imo. "FDA agreed ..." (repeated)
Have to say, that is a strong post. If all that is true, at this point a long has to hope in some seriously positive result coming up or that some big Pharma type deep pockets will sense real value in the drug.
(To add: I am long with more shares and higher cost-basis than by any means good for my account, but somewhat resigned to whatever be the outcome. My investment was that LL would make it in Covid, especially critical based on eINDs, with other indications being an insurance. Now the insurance has to come through somehow.)
Didn't know this. Good info. Will be interesting to see how the FDA responds.
I looked at the 4/11 news and it says:
As of today, the daily chart shows we are holding the gains of Monday. Past two days have been consolidating above the close of Monday. High volume yesterday but whatever was sold was bought back up and the price did not drop. Today much less volume but maintaining. Nothing yet to suggest a total dump is coming to return us to the .20s. New people have bought to stay in, and awaiting news to move higher.
The beauty here is that Cytodyn PR dept is completely hands off till now. The news is advertised in other sites, of established reputation - not a restatement of what the Company PRs. Different strategy but you need something substantial for it to happen in the right way. Seems that is the case.
"not simply Cytodyn". Still UCLA-led team of researchers. Dr. Yang did not resign his position there; he receives funding there as well. And is responsible to their rules and expectations when conducting research. And their name is on the line. The market knows it.
Facts. UCLA research, not simply Cytodyn.
"A UCLA-led team of researchers" published upfront in UCLAhealth.org.
No one is calling it a phase 3.
Dr. Yang means UCLA's name is on the line. Not a joke.
Three things:
1. Fox News
2. Dr. Recknor only Senior Research Director and no longer Executive Officer
3. Letter of correction
And an incredible change in SP that apparently happened on its own.
No connection?
If someone said we will pick a random day in the month to give these three news items after-hours and we will look at SP change each day during regular market hours, then if the result of the trial is what we have: is it statistically significant?
Much more dignified and signaling self-respect than a "Forgive us Master. Its all that CEO's fault!" (I would not have been surprised if it had more of that flavor.)
"This is what FDA said/identified as problematic ... we are an investigational drug only." We are posting this at FDA request. That's all folks.
My reading:
This is a placebo-controlled study albeit small (55 patients, randomly selected). Call it a small phase 2 type. But the key point is that Dr. Yang is still saying that LL seems to be doing right for Long Covid patients. That likely means the LL arm is doing better than placebo. But when they look at the immune markers, the data is showing something unexpected, that the improvement in the LL patients correlates with an improvement in immune receptors/functions, whereas the same effect is not seen in placebo patients. So they are guessing: Long Covid is suppressing immune system for some people (and their struggles are consequence of imbalanced immune system) and LL is somehow is allowing a restabilization of CCR5 expression which in turn gets the immune system back in form.
Complex. But positive data from the trial that LL is helping.
"Patients who improved were those who started with low CCR5 on their T cells, suggesting their immune system was less active than normal, and levels of CCR5 actually increased in people who improved. This leads to the new hypothesis that long COVID in some persons is related to the immune system being suppressed and not hyperactive, and that while blocking its activity, the antibody can stabilize CCR5 expression on the cell surface leading to upregulation of other immune receptors or functions."
He is the Senior Director of Research and Development. That's how Longs are anyway seeing him, not as "executive officer" whatever that means. How does not being an Officer take away from his Research Director authority within the Company? He perhaps doesn't want to be bothered by paperwork and formalities with SEC. (?)
But if its not the manipulators trying to dump at a higher price, then who? My mind automatically goes to some sort of insider-news leak. There has to be a more legal explanation. Some large fund or group decided to systematically buy up the price today, starting around 12 PM. The chart looks very deliberate (in 20 min for ex.) But why all of a sudden, if they knew nothing more than us? Or a large short-seller group decided to cover and move on. ??
Ok. Thanks. Pardon the ignorance. My mind is in a daze. Should have known the answer to the first part. Did not know we have to approve the buyout as well.
So, if people (longs) talk of buyout, suppose we want a $3 buyout price, whoever buys out has to pay 718 mill x 3 = 2.15 billion. That's how I understand. It won't happen without results. What realistically is the type of proof we need to give to be an actual buyout candidate, and what would longs here actually be happy as a buyout price, given our precarious situation now?
(I don't quite follow who exactly they give that money to and why exactly that will raise the stock price to $3 in the open market. The shareholders are "owning" the stock and the buyer certainly isn't trading with us directly. But that's a general topic.)
Ok, thanks again.
(Just saw that market cap is easily available like in yahoo finance. Other info like OS, float not as easy to find. But if we take the MC ~ 176 mill and divide by share price 0.245, we get 718 mill shares as outstanding.)
Anyone know how we can find the # shares outstanding, market cap and float size for CYDY? My usual method is to go to finviz but they don't carry that info for the OTC company. Can you point out the exact documents or SEC filings where this info will be available?
Ok, thanks.
The DSMC was expected to tell the company of the interim analysis and those cardiac events, this month. Is the company obligated to tell us of the outcome within a certain number of days? That is, they can't simply sit on the information for 2 or 3 weeks? Either they tell us the trial continues or there is a safety concern from the interim that caused us to stop the trial. What should we realistically expect - in terms of the legal obligation to provide info to the shareholder?
Fidelity says 0.0349 change, +13.17%. Its just sporadic buying but with some "high" volume minutes towards market close. Somebody thought it worth the investing at this price. At least the technical chart changes nicely in the daily.
For Brazil, they said there were 2 safety (cardiac) events due to which the company decided to pause out of abundant precaution - we do not know whether these were in LL arm or placebo. Doctors there say this is typical of a covid-related event. The DSMC meeting is in early April after which (if cleared) we are expected to resume. Right now we have 16 critical enrollments and 77 severe enrollments. However due to vaccination etc, Brazil situation is dramatically improved etc. (which suggests we may not have quick enrollment thereafter), and they are monitoring Covid as it moves from pandemic to endemic stage. No info regarding finances.
the fda holds; they needed to say something to reassure us - whether it worked or not.
"That's all the questions we have"
Well, that's a lie. But ok, at least not a "we are doomed" session by any means.
“CytoDyn is committed to FDA compliance,” said Scott A. Kelly
Is Pausing Brazil trials a way of showing compliance to FDA? Some sort of implicit head-nod between fda and company, as an extension to the covid hold in US. Or something completely independent?